OneSource Specialty Pharma Share Price

Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The Company name was then changed to Stelis Biopharma Private Limited, pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies. The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited dated July 31, 2021,. Subsequently, the name was changed to its present Onesource Specialty Pharma Limited on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.In FY 202425, a Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024. Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively. Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies. In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re. 1/ each have been allotted and issued. At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers endtoend Contract Development and Manufacturing Operations (CDMO) services across all phases of preclinical and clinical development and commercial supply of biologics. Company has 5 globally compliant Manufacturing Facilities. Customer list includes some of the top pharmaceutical generic companies, innovator pharmaceutical and biopharmaceutical companies, small biotechs and dedicated RD houses, spread across the globe.Company completed execution of highvalue projects across Biologics, Injectables, and Oral Technologies in FY 2025.

For the full year FY2025–2026, revenue reached ₹1462.33 crore and profit touched at ₹-17.28 crore. As of Mar '26, OneSource Specialty Pharma’s market capitalisation stood at ₹21,039.22 crores. Shareholding as of Mar '26 shows promoters holding 30.5%, with FIIs at 17.5%, DIIs at 20.6%, and public at 31.4%.